通过销售1 160万股,每股21.50美元,Centessa制药公司筹集了2.5亿美元,收入为发展神经和神经精神病治疗提供资金。 Centessa Pharmaceuticals raised $250 million by selling 11.6 million shares at $21.50 each, with proceeds funding development of treatments for neurological and neuropsychiatric disorders.

Centessa Pringulations公司以1 160万美元的公开供货价为1 160万美国保管股,每股21.50美元,在开支前筹集了大约2.5亿美元的总收益。 Centessa Pharmaceuticals priced a public offering of 11.6 million American Depositary Shares at $21.50 each, raising about $250 million in gross proceeds before expenses. 由Jefferies、Leerink Partners、Evercore ISI和Guggenheim证券公司管理的这项提议预计于2025年11月14日终止,但须符合习惯条件。 The offering, managed by Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities, is expected to close on November 14, 2025, subject to customary conditions. 承保人可以选择30天购买多达170万股的额外股份。 Underwriters have a 30-day option to buy up to 1.7 million additional shares. 收益将支持该公司用于治疗神经和神经精神疾病的素受体2激动剂方案的临床开发. Proceeds will support clinical development of the company’s orexin receptor 2 agonist programs for neurological and neuropsychiatric disorders. 该发行是在2024年9月11日提交给美国证券交易委员会的S-3表格下注册的. The offering is registered under a Form S-3 filed with the SEC on September 11, 2024.